Anand Rathi analyst picks three stocks for September 16
Ganesh Dongre, Senior Manager - Technical Research at Anand Rathi Shares and Stock Brokers Limited, has recommended PN Gadgil Jewellers, Mankind Pharma and BEML for September 16, 2026. PN Gadgil Jewellers: buy between Rs 600-620, stop loss Rs 580, targets Rs 650 and Rs 670. Mankind Pharma: buy Rs 2,250-2,280, stop loss Rs 2,200, targets Rs 3,380 and Rs 2,450. BEML: buy Rs 2,060-2,080, stop loss Rs 2,020, targets Rs 2,280 and Rs 2,350. The views are the analyst's own.
Source
Times of India — Top · read the original report ↗
Desk check · some claims need care
What the desk checked (5)
- PN Gadgil Jewellers, Mankind Pharma and BEML are recommended buys for September 16, 2026. — Attributed in source to Ganesh Dongre, Senior Manager - Technical Research, Anand Rathi Shares and Stock Brokers Limited.
- PN Gadgil Jewellers: buy Rs 600-620, stop loss Rs 580, targets Rs 650 and Rs 670. — Figures appear as given in the source; no independent verification possible.
- Mankind Pharma: buy Rs 2,250-2,280, stop loss Rs 2,200, targets Rs 3,380 and Rs 2,450. — Figures as printed in source, but Rs 3,380 conflicts with the source's own upside range of Rs 2,350-2,400; possible typographical error.
- BEML: buy Rs 2,060-2,080, stop loss Rs 2,020, targets Rs 2,280 and Rs 2,350, with Rs 2,080 the key breakout level. — Figures appear in source; rationale cites defence, railway and infrastructure exposure, unverified externally.
- The views are the analyst's own and not those of the publisher. — Explicit disclaimer carried in the source text.
Analysts’ view opinion
This is a short-horizon technical call, not a verdict on India's economy or on the underlying earnings power of the three companies. What is economically interesting is the thematic mix: a jewellery retailer (consumption and gold prices), a domestic pharma player (defensive, steady demand) and a state-linked engineering firm tied to defence, railways and infrastructure (public capex). The risk-reward is defined narrowly — tight stop losses of 3-4% against upside targets of roughly 8-13% — which tells you the analyst is trading momentum, not investing in fundamentals.
- The three picks together sketch the market's current comfort zones: discretionary consumption, healthcare defensives and government-led capital spending.
- BEML's cited exposure to defence, railway and infrastructure means its share price is effectively a proxy for the pace of public order flow and project execution, which the story does not quantify.
- PN Gadgil's fortunes are structurally linked to gold prices and festive-season jewellery demand — high gold prices can lift value sales while squeezing volumes, a tension not addressed here.
- Mankind Pharma sits in the steadier part of the cycle, where domestic formulations demand is less sensitive to growth swings, which is why it reads as a defensive leg in the basket.
- One target range for Mankind (Rs 3,380 listed alongside Rs 2,450) looks internally inconsistent with the entry band, so readers should treat the numbers as indicative levels rather than precise arithmetic.
What to watch — Watch whether the stated breakout levels — around Rs 630 for PN Gadgil, Rs 2,230-2,250 for Mankind and Rs 2,080 for BEML — hold on rising volumes, since technical calls of this type live or die on follow-through rather than on any new economic data.
The story establishes only one analyst's chart-based levels and targets; it offers no earnings, valuation, order-book or macro data, no track record for these calls, and no assurance that any target will be met.
Deep dive
Research brief · 8 facts · 1 dates · exam-readyThe brief
Context
This is a daily technical-analysis stock call published in the business pages. Ganesh Dongre, Senior Manager - Technical Research at Anand Rathi Shares and Stock Brokers Limited, has named three stocks — PN Gadgil Jewellers, Mankind Pharma and BEML — as his picks for September 16, 2026, with buy ranges, stop-loss levels and price targets. Such recommendations rest on chart-based tools like trendline breakouts, moving averages, support/resistance zones and the MACD indicator, rather than company financials. The source carries a disclaimer that these are the analyst's own views and not those of the publication.
Key facts
- PN Gadgil Jewellers: buy between Rs 600-620, stop loss Rs 580, targets Rs 650 and Rs 670.
- PN Gadgil Jewellers shows a trendline breakout in the Rs 590-610 zone on the daily chart; a decisive close above Rs 630 would strengthen bullish momentum.
- The MACD for PN Gadgil Jewellers is moving into an oversold zone, which the analyst says could support a momentum recovery.
- Mankind Pharma: buy between Rs 2,250-2,280, stop loss Rs 2,200, targets Rs 3,380 and Rs 2,450 as stated in the source.
- Mankind Pharma's Rs 2,230-2,250 zone is flagged as immediate support; a decisive weekly close above it could open upside towards Rs 2,350-2,400.
- BEML: buy between Rs 2,060-2,080, stop loss Rs 2,020, targets Rs 2,280 and Rs 2,350.
- BEML's key breakout level is the previous swing high of Rs 2,080; a move above it with rising volumes would signal renewed buying, with an upside target of Rs 2,350.
- The report notes BEML's exposure to defence, railway and infrastructure themes, and calls its setup 'cautiously bullish'.
Timeline
- September 16, 2026Date for which Ganesh Dongre of Anand Rathi recommends PN Gadgil Jewellers, Mankind Pharma and BEML with specified buy ranges, stop losses and targets.
Who has a stake
- Ganesh Dongre, Senior Manager - Technical Research, Anand Rathi Shares and Stock Brokers Limited — Author of the calls; his technical reading and credibility are tested by whether the stated targets or stop losses are hit.
- Retail traders and short-term investors — May act on the buy ranges and stop losses; face direct financial gain or loss from the trades.
- PN Gadgil Jewellers — Its share price is said to show a trendline breakout in the Rs 590-610 zone with resistance up to Rs 670.
- Mankind Pharma — Described as maintaining a positive technical outlook after a strong recovery from lower levels.
- BEML — Public-sector player with defence, railway and infrastructure exposure; consolidating after a recent correction with Rs 2,080 as the breakout level.
- The publication (The Times of India, per disclaimer) — Carries the recommendation but explicitly states the opinions are the analyst's own and not its views.
Why it matters
Technical calls like these shape short-term retail trading behaviour in a market with a rapidly widening base of individual investors. Understanding what a stop loss, support zone or breakout level actually signals helps readers judge risk rather than follow numbers blindly — especially where, as here, one target figure (Rs 3,380 for Mankind Pharma) sits oddly against the stock's stated upside zone of Rs 2,350-2,400.
UPSC angle
Prelims pointers
- Technical analysis relies on price charts and indicators such as MACD, moving averages, and support/resistance levels, not on company fundamentals.
- Stop loss: a pre-set exit price to cap losses if the trade moves against the buyer — Rs 580 for PN Gadgil Jewellers, Rs 2,200 for Mankind Pharma, Rs 2,020 for BEML.
- BEML is linked in the source to defence, railway and infrastructure themes.
- A 'breakout' is a decisive move above a resistance or swing high — Rs 2,080 for BEML, above Rs 630 for PN Gadgil Jewellers.
- Media disclaimers note that analyst recommendations are personal views and do not represent the publication's stance.
Mains framing
Daily broker recommendations of the kind carried here illustrate how technical analysis functions in Indian equity markets: instead of assessing earnings or balance sheets, the analyst reads price behaviour — a trendline breakout in the Rs 590-610 band for PN Gadgil Jewellers, sustained trading above short- and medium-term moving averages for Mankind Pharma, and a sideways consolidation with Rs 2,080 as the breakout trigger for BEML. The appeal lies in clear, actionable numbers: an entry band, a stop loss to cap downside, and staged targets. The risks are equally clear. Such calls are inherently short-horizon and probabilistic, depend on the "broader market structure remaining supportive" as the analyst himself concedes, and can be misread by inexperienced investors as assured returns; the Mankind Pharma target sequence in this source (Rs 3,380 and Rs 2,450, against a stated upside zone of Rs 2,350-2,400) shows how even published figures need careful reading. The way forward for readers is disciplined use of stop losses, position sizing, verification of numbers against exchange data, and treating the mandated disclaimer — that these are the analyst's own views — as substantive rather than formal.
Key terms
- Stop loss
- A pre-decided price at which a trader exits to limit losses; here Rs 580, Rs 2,200 and Rs 2,020 for the three stocks.
- MACD
- Moving Average Convergence Divergence, a momentum indicator; said to be entering an oversold zone for PN Gadgil Jewellers.
- Trendline breakout
- A decisive price move beyond a drawn trendline, read as a sign of a strengthening trend — cited in the Rs 590-610 zone for PN Gadgil Jewellers.
- Support and resistance
- Price zones where buying or selling pressure typically emerges; Rs 2,230-2,250 is Mankind Pharma's support, Rs 605-670 PN Gadgil's resistance.
- Swing high
- A recent local price peak; BEML's previous swing high of Rs 2,080 is flagged as the key breakout level.
- BEML
- A listed company with exposure to defence, railway and infrastructure themes, per the source.
Practice questions
- What is technical analysis, and how do indicators such as MACD, moving averages and support-resistance zones differ from fundamental analysis in guiding investment decisions?
- Discuss the role and risks of broker-issued short-term stock recommendations for retail investors in India, and the safeguards such as stop losses and disclaimers.
- Examine why public-sector firms with defence, railway and infrastructure exposure, such as BEML, attract thematic investor interest.
Grounded only in the source report — figures and dates are the source's, not inferred.